Men’s health has often been limited to discussions about prostate, erectile dysfunction, and testosterone levels. This perspective is narrow. A more comprehensive model connects metabolic health, hormones, sexual function, mental well-being, and everyday self-care. These elements are interconnected and frequently influence one another.
Glucagon-like peptide-1 (GLP-1) therapeutics have accelerated this shift. Medications like semaglutide and tirzepatide have transformed obesity treatment from a focus on willpower to one based on biology, chronic disease management, and measurable risk reduction. For some men, significant weight loss can improve blood pressure, glucose control, sleep apnea, mobility, and cardiovascular status. It also addresses obesity-related declines in testosterone levels. The key takeaway is this: Before concluding that fatigue, reduced libido, or low testosterone necessitates hormone replacement, clinicians should consider the contributory metabolic issues.
Testosterone remains important, but testosterone therapy should not serve as a quick solution for all symptoms linked to aging, obesity, stress, or poor sleep. True hypogonadism requires the presence of compatible symptoms and consistently low testosterone levels. Men deserve discussions about fertility, treatment goals, monitoring, and alternatives. We should focus on restoring health rather than chasing arbitrary laboratory numbers or internet-driven notions of masculinity.
Sexual health should be part of this conversation. Erectile dysfunction is more than just a quality-of-life issue; it can indicate vascular disease, diabetes, medication effects, hormonal disorders, psychological distress, or other health concerns. Indeed, inquiries about sexual function should be integrated into preventive medicine rather than relegated to a half-hearted question. Men seeking help for erectile dysfunction may present an early opportunity to detect cardiometabolic disease.
The other pillar, though perhaps the least glamorous, is the most crucial: self-care. Men must be empowered to view sleep, nutrition, resistance exercise, stress management, preventive screenings, social connections, and mental health as vital interventions rather than signs of weakness or indulgence. While medication can be beneficial, it cannot replace these foundational aspects.
This new model supports but cautions the rapidly growing “optimization” industry. GLP-1 drugs and testosterone are potent tools, but they should not become consumer products prescribed without proper diagnosis, follow-up, or consideration of the whole person. Rapid weight loss without sufficient nutrition and exercise can lead to a loss of lean mass. Testosterone prescribed without thorough evaluation overlooks the actual cause of symptoms. Ignoring cardiovascular and metabolic health when addressing sexual dysfunction overlooks important warning signs.
The future of men’s health must move beyond isolated prescriptions. It should involve measuring waistlines and blood pressure, monitoring sleep and sexual function, investigating symptoms before making diagnoses, treating obesity as a chronic disease, using testosterone when clinically warranted, protecting muscle and function during weight loss, and discussing mental well-being without stigma.
Men do not need more health hype; they need integrated care. The new approach to men’s health is not about becoming younger, leaner, stronger, or more “optimized” at any cost. It is about helping men live longer, function better, maintain relationships, recognize risks earlier, and remain actively engaged in their health.
Olumuyiwa Bamgbade is an accomplished health care leader with a strong focus on value-based health care delivery. A specialist physician with extensive training across Nigeria, the United Kingdom, the United States, and South Korea, Dr. Bamgbade brings a global perspective to clinical practice and health systems innovation.
He serves as an adjunct professor at academic institutions across Africa, Europe, and North America and has published 45 peer-reviewed scientific papers in PubMed-indexed journals. His global research collaborations span more than 20 countries, including Nigeria, Australia, Iran, Mozambique, Rwanda, Kenya, Armenia, South Africa, the U.K., China, Ethiopia, and the U.S.
Dr. Bamgbade is the director of Salem Pain Clinic in Surrey, British Columbia, Canada—a specialist and research-focused clinic. His work at the clinic centers on pain management, health equity, injury rehabilitation, neuropathy, insomnia, societal safety, substance misuse, medical sociology, public health, medicolegal science, and perioperative care.
